Medivir CTCL candidate headed for Phase III

Medivir AB (SSE:MVIR B) reported results of a Phase II study of remetinostat (formerly SHAPE) to treat early stage cutaneous T cell lymphoma (CTCL) and said it plans to start a Phase III trial by YE17, pending discussions with regulators.

The company said the top dose of remetinostat, twice-daily 1% gel, led to responses in eight (40%) of 20 patients, with one complete response. A daily dose of 1% and twice-daily 0.5% led to 20% and 25% response rates, respectively, with no complete responses...